GoAI
Get started
NEXGEL, Inc. logo

NEXGEL, Inc.

NXGL

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Previous close

$0.33

−$0.0573 · -14.79%

Aug 21, 4:00 PM ET

Pre-market

$0.3029

−$0.0271 · -8.21%

Aug 24, 6:44 AM ET

NXGL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

21

Weakening

Sentiment

56

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Adam R. Levy
Listed since
Dec 22, 2021
Employees
19

Market position

Day range

Current $0.33

52-week range

Current $0.33

Open
$0.3635
Previous close
$0.3873
Volume
350.66K
1.02× average
Average volume
343.5K
Average daily volume
Market cap
2.8M USD
Beta
0.77
Market reference 1
50-day average
$0.4735
-30.30% below average
200-day average
$0.9961
-66.87% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
15.42M USD
P/E (TTM)
-0.46×
P/B (TTM)
0.6×
P/S (TTM)
0.23×
EV / EBITDA
-7.28×
Earnings yield
-23.72%
Free cash flow yield
-10.91%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
35.07%
Operating margin
-44.77%
Net margin
-51.26%
Return on equity
-67.28%
Return on assets
-28.68%
Return on invested capital
-42.01%

Financial health

Debt / equity
1.51×
Current ratio
1.47×
Altman Z-score
-1.66
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends71%-56%-183%-310%Gross margin, FY2021: 0.52%Gross margin, FY2022: 12.50%Gross margin, FY2023: 9.15%Gross margin, FY2024: 31.63%Gross margin, FY2025: 39.48%Operating margin, FY2021: -165.70%Operating margin, FY2022: -163.48%Operating margin, FY2023: -85.03%Operating margin, FY2024: -40.91%Operating margin, FY2025: -29.35%Net margin, FY2021: -277.89%Net margin, FY2022: -231.74%Net margin, FY2023: -77.21%Net margin, FY2024: -37.76%Net margin, FY2025: -26.27%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 0.52%. Gross margin FY2022 12.50%. Gross margin FY2023 9.15%. Gross margin FY2024 31.63%. Gross margin FY2025 39.48%. Operating margin FY2021 -165.70%. Operating margin FY2022 -163.48%. Operating margin FY2023 -85.03%. Operating margin FY2024 -40.91%. Operating margin FY2025 -29.35%. Net margin FY2021 -277.89%. Net margin FY2022 -231.74%. Net margin FY2023 -77.21%. Net margin FY2024 -37.76%. Net margin FY2025 -26.27%.

Income trends

Revenue

11.42M USD+31.46%

Operating income

−3.35M USD+5.68%

Net income

−3M USD+8.56%
Income trends across reported periods13.04M USD6.57M USD104.1K USD−6.36M USDRevenue, FY2021: 1.55M USDRevenue, FY2022: 2.05M USDRevenue, FY2023: 4.09M USDRevenue, FY2024: 8.69M USDRevenue, FY2025: 11.42M USDOperating income, FY2021: −2.57M USDOperating income, FY2022: −3.35M USDOperating income, FY2023: −3.48M USDOperating income, FY2024: −3.55M USDOperating income, FY2025: −3.35M USDNet income, FY2021: −4.31M USDNet income, FY2022: −4.75M USDNet income, FY2023: −3.16M USDNet income, FY2024: −3.28M USDNet income, FY2025: −3M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.55M USD. Revenue FY2022 2.05M USD. Revenue FY2023 4.09M USD. Revenue FY2024 8.69M USD. Revenue FY2025 11.42M USD. Operating income FY2021 −2.57M USD. Operating income FY2022 −3.35M USD. Operating income FY2023 −3.48M USD. Operating income FY2024 −3.55M USD. Operating income FY2025 −3.35M USD. Net income FY2021 −4.31M USD. Net income FY2022 −4.75M USD. Net income FY2023 −3.16M USD. Net income FY2024 −3.28M USD. Net income FY2025 −3M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue11.42M USD8.69M USD4.09M USD2.05M USD1.55M USD
Cost of goods sold6.91M USD5.94M USD3.72M USD1.79M USD1.54M USD
Gross profit4.51M USD2.75M USD374K USD256K USD8K USD
Research and development2K USD78K USD103K USD367K USD31K USD
Selling, general, and administrative7.86M USD5.91M USD3.4M USD2.82M USD2.41M USD
Operating expenses7.86M USD6.3M USD3.85M USD3.6M USD2.58M USD
Interest expense34K USD81K USD15K USD1.34M USD2M USD
Depreciation and amortization740K USD480K USD443K USD301K USD138K USD
Operating income−3.35M USD−3.55M USD−3.48M USD−3.35M USD−2.57M USD
Net income−3M USD−3.28M USD−3.16M USD−4.75M USD−4.31M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-101.24%
11 comparable reports
Latest EPS result
-0.4
Estimate -0.12 · Miss by 233.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.01-0.15-0.3-0.44Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 24, 2025: actual -0.08, estimate -0.13, surprise +38.46%, Beat. Q2 2025, reported May 13, 2025: actual -0.09, estimate -0.1, surprise +10.00%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.09, estimate -0.01, surprise -800.00%, Miss. Q4 2025, reported Nov 11, 2025: actual -0.08, estimate -0.09, surprise +11.11%, Beat. Q1 2026, reported Mar 31, 2026: actual -0.11, estimate -0.09, surprise -22.22%, Miss. Q2 2026, reported May 13, 2026: actual -0.11, estimate -0.07, surprise -57.14%, Miss. Q3 2026, reported Aug 14, 2026: actual -0.4, estimate -0.12, surprise -233.33%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate -0.04, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.24M5.6M3.95M2.31MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 24, 2025: actual 3.04M USD, estimate 2.99M USD, surprise +1.60%, Beat. Q2 2025, reported May 13, 2025: actual 2.81M USD, estimate 3.08M USD, surprise -8.90%, Miss. Q3 2025, reported Aug 12, 2025: actual 2.88M USD, estimate 3.45M USD, surprise -16.41%, Miss. Q4 2025, reported Nov 11, 2025: actual 2.93M USD, estimate 3.24M USD, surprise -9.44%, Miss. Q1 2026, reported Mar 31, 2026: actual 2.8M USD, estimate 3.24M USD, surprise -13.55%, Miss. Q2 2026, reported May 13, 2026: actual 2.65M USD, estimate 3.91M USD, surprise -32.21%, Miss. Q3 2026, reported Aug 14, 2026: actual 3.69M USD, estimate 4.32M USD, surprise -14.58%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate 6.9M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution
Maxim GroupmaintainBuy

NXGL news

globenewswire.com

NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE

LANGHORNE, Pa. , Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a series of leadership, governance and strategic initiatives designed to strengthen operational…

Read source
globenewswire.com

NEXGEL Reports Second Quarter 2026 Financial Results

LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle,…

Read source
globenewswire.com

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

LANGHORNE, Pa. , June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content…

Read source

NXGL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding NXGL

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
20.31K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
76.69
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
47.52
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%

Continue in GoAI

Research NXGL

research.disclaimer